" /> Tildrakizumab - CISMeF





Preferred Label : Tildrakizumab;

NCIt synonyms : Immunoglobulin G1, Anti-(Human Interleukin-23); Humanized Mouse Monoclonal Gamma1 Heavy Chain (219-214')-Disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (225-225'':228-228'')-Bisdisulfide; Immunoglobulin G1, Anti-(Human Interleukin 23) (Human-Mus Musculus Monoclonal Heavy Chain), Disulfide with Human-Mus Musculus Monoclonal Light Chain, Dimer;

NCIt definition : A humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. Upon subcutaneous administration, tildrakizumab targets and binds to the p19 subunit of IL-23, thereby neutralizing IL-23 and preventing the binding of IL-23 to its receptor. This inhibits IL-23-mediated signaling and inhibits differentiation of CD4 positive T-cells into Th1 and Th17 cells. This prevents Th1- and Th17-mediated responses and cytokine production. This may prevent or reduce symptoms and severity of graft versus host disease (GVHD). IL-23, a pro-inflammatory cytokine that play a key role in the regulation of the immune system, is upregulated in immune-mediated inflammatory disorders. Both Th1 and Th17 cells play a crucial role in GVHD.;

UNII : DEW6X41BEK;

CAS number : 1326244-10-3;

Molecule name : MK-3222;

NCI Metathesaurus CUI : CL553831;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
11/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.